diabetes glp-1 agonist Receptor Agonists: The New Wave in Management Classification of glucagon-like peptide-1 receptor

Early post-marketing surveillance and case reports raised initial concerns, prompting extensive investigation through randomised controlled trials, observational studies, and meta-analyses

The pharmacokinetic variability is also high (coefficient of variation 38% vs 12% for injection), meaning dose delivery is less predictable

These agents act through multiple mechanisms, including direct cardioprotection, vasodilation, natriuresis, weight reduction, lipid profile improvement, anti-inflammatory effects, renal protection, reduction in plaque formation, and neurohormonal regulation

The question is not whether this market will keep growingit will

Currently, 30% of Americans interested in weight loss say they do not use a GLP-1 medication because of cost or insurance coverage, as insurers cut back on GLP-1 coverage